Alvotech (ALVO)

NASDAQ: ALVO · IEX Real-Time Price · USD
12.00
+0.02 (0.17%)
At close: Jan 31, 2023, 4:00 PM
11.38
-0.62 (-5.17%)
After-hours: Jan 31, 2023, 4:00 PM EST
0.17%
Market Cap 2.98B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 248.65M
EPS (ttm) 0.24
PE Ratio 50.00
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 98,077
Open 12.03
Previous Close 11.98
Day's Range 11.86 - 12.08
52-Week Range 5.20 - 14.04
Beta -0.15
Analysts Buy
Price Target 13.06 (+8.83%)
Earnings Date n/a

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond... [Read more]

Sector Healthcare
Founded 2013
Employees 784
Stock Exchange NASDAQ
Ticker Symbol ALVO
Full Company Profile

Financial Performance

In 2021, Alvotech's revenue was $36.77 million, a decrease of -44.80% compared to the previous year's $66.62 million. Losses were -$101.50 million, -40.31% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $13.06, which is an increase of 8.83% from the latest price.

Price Target
$13.06
(8.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC (“GHH”), the healthcare division of Yas Holding LLC, today announced that the Saudi Food & Drug Au...

1 week ago - GlobeNewsWire

Alvotech Completes $137 Million Private Share Placement

REYKJAVIK, Iceland, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

1 week ago - GlobeNewsWire

Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji Pharma Co., L...

2 weeks ago - GlobeNewsWire

Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic st...

3 weeks ago - GlobeNewsWire

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

REYKJAVIK, Iceland & PARSIPPANY, N.J.--(BUSINESS WIRE)--Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...

3 weeks ago - Business Wire

Update on U.S. Regulatory Status of AVT02, Alvotech's Proposed High-Concentration, Interchangeable Biosimilar to Humira®

REYKJAVIK, Iceland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

1 month ago - GlobeNewsWire

Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT

Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds. The aggregate principal amount is approximately US$70 million,...

1 month ago - GlobeNewsWire

Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field

Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds. The aggregate principal amount is approximately US$70 million,...

1 month ago - GlobeNewsWire

Alvotech Completes $59.7 Million Private Placement

REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

1 month ago - GlobeNewsWire

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

REYKJAVIK, Iceland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

1 month ago - GlobeNewsWire

Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

REYKJAVIK, Iceland and BAD VILBEL, Germany, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and STADA are contributing to the availability of high-quality biologic treatments in Europe by ro...

2 months ago - GlobeNewsWire

Nasdaq Iceland Approves the Request for Trading of Alvotech's Shares on the Main Market

Nasdaq Iceland has approved Alvotech S.A's (“Alvotech”) request for admission to trading of its shares on the Nasdaq Iceland Main Market (“Main Market”). Alvotech's shares will be admitted to trading ...

2 months ago - GlobeNewsWire

Alvotech Announces Changes to its Leadership Team

Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer

2 months ago - GlobeNewsWire

Alvotech Submits its Application for Admission of the Company's Shares to Trading on Nasdaq Iceland Main Market

Alvotech S.A. (“Alvotech”) has submitted its application to Nasdaq Iceland for admission of its shares for trading on the Nasdaq Iceland Main Market under the ticker symbol “ALVO”. The application awa...

2 months ago - GlobeNewsWire

Alvotech Secures Financing Facilities of Approximately $136 Million

Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investors

2 months ago - GlobeNewsWire

Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update

REYKJAVIK, Iceland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

2 months ago - GlobeNewsWire

Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

Reykjavik, Iceland and Mumbai, India (November 14, 2022) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldw...

2 months ago - GlobeNewsWire

Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02

2 months ago - GlobeNewsWire

Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results ...

3 months ago - GlobeNewsWire

Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November

REYKJAVIK, Iceland , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announce...

3 months ago - GlobeNewsWire

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

Expanded partnership covers biosimilar candidates in immunology and oncology

3 months ago - GlobeNewsWire

Alvotech's Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

REYKJAVIK, Iceland, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

3 months ago - GlobeNewsWire

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corp...

4 months ago - GlobeNewsWire

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

REYKJAVIK ICELAND; BAD VILBEL, GERMANY (September 22, 2022) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wor...

4 months ago - GlobeNewsWire

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication f...

5 months ago - GlobeNewsWire